Learning from older drug modalities accelerates viral process development
Andrew Tustian, EngD, director of viral process development at Regeneron Pharmaceuticals, spoke with ScienceBoard.net about accelerating process development for adeno-associated viruses by modifying strategies from older modalities. Read More
How one company aims to make bedside cell therapies a reality
SQZ Biotech is developing high-throughput technology that can manufacture novel cell therapy products in under 24 hours. Founder and CEO Armon Sharei, PhD, spoke with ScienceBoard.net recently at Biotech Week Boston 2021. Read More
End-to-end automation of closed manufacturing can make cell therapies more accessible
BOSTON - Cellares is building a cell manufacturing platform that fully automates and closes the process, according to co-founder and CEO Fabian Gerlinghaus. ScienceBoard.net spoke with Gerlinghaus following a presentation at the Cell and Gene Manufacturing and Commercialization event, which is part of Biotech Week Boston 2021. Read More
New tools are needed for next-gen gene therapies
BOSTON - Delivering next-generation viral vectors for use in gene therapies requires that scientists reenvision the tools and process modalities that could be leveraged to make gene therapy a reality, according to Stefano Menegatti, PhD, associate professor at North Carolina State University. Menegatti spoke with ScienceBoard.net during the BioProcess International conference in Boston. Read More
Biotech Week Boston highlights research progress in cell and gene therapy
At Biotech Week Boston, ScienceBoard.net Editor-in-Chief Samantha Black, PhD, spoke with experts in cell and gene therapy technologies. Read More
Celldom has its eye on low-cost, scalable single-cell analysis
Celldom, a startup based in Durham, NC, has developed a low-cost, high-throughput, single-cell analysis platform designed to investigate and classify rare cells associated with diseases like cancer. The company is one of 10 semifinalists in the BioTools Innovator accelerator contest. We spoke with co-founder and CEO Benjamin Yellen as part of our exclusive coverage of the competition. Read More
Quantitative image analysis provides confidence in drug development
Olga Kubassova, PhD, CEO of Image Analysis Group, spoke with ScienceBoard.net about how computational analysis is improving clinical trial imaging. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter